Literature DB >> 26616866

Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.

Harry Alexopoulos1, Eleni I Kampylafka1, Penelope Fouka2, Ioanna Tatouli1, Sofia Akrivou1, Panagiotis K Politis3, Haralampos M Moutsopoulos1, Athanasios G Tzioufas1, Marinos C Dalakas4.   

Abstract

Anti-aquaporin-4 autoantibodies are specific for the neuromyelitis optica spectrum disorders (NMOSD) and they have also been described in patients with systemic lupus erythematosus (SLE) with neurological signs consistent with NMOSD. Our objective was to test for the presence and pathogenicity of anti-AQP4 antibodies in SLE patients without neurological disease. Sera from 89 non-CNS-SLE patients were screened for anti-AQP4 autoantibodies. Two of the 89 patients were positive. Archived samples dating back 11 years were also positive. A brain and spinal cord MRI did not reveal any NMOSD-compatible lesions. An in vitro cytotoxicity assay showed that either sera or purified IgG from these patients induced a complement-mediated damage in cultured astrocytes comparable to antibodies obtained from typical NMO patients. We conclude that AQP4-antibodies can be present in SLE patients and persist for many years, without concurrent clinical or radiological NMOSD signs. It is unclear why the anti-AQP4 antibodies did not induce CNS disease.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AQP4; Astrocytes; Autoantibodies; Neuromyelitis optica; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 26616866     DOI: 10.1016/j.jneuroim.2015.10.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.

Authors:  Richard K Burt; Roumen Balabanov; Xiaoqiang Han; Carol Burns; Joseph Gastala; Borko Jovanovic; Irene Helenowski; Jiraporn Jitprapaikulsan; James P Fryer; Sean J Pittock
Journal:  Neurology       Date:  2019-10-02       Impact factor: 9.910

Review 2.  Headache in Neuromyelitis Optica.

Authors:  Alina Masters-Israilov; Matthew S Robbins
Journal:  Curr Pain Headache Rep       Date:  2017-04

Review 3.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

Review 4.  Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

Authors:  Kevin Didier; Loïs Bolko; Delphine Giusti; Segolene Toquet; Ailsa Robbins; Frank Antonicelli; Amelie Servettaz
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

Review 5.  Neurological Disease in Lupus: Toward a Personalized Medicine Approach.

Authors:  Sarah McGlasson; Stewart Wiseman; Joanna Wardlaw; Neeraj Dhaun; David P J Hunt
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 8.786

6.  Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity.

Authors:  Panos Stathopoulos; Anne Chastre; Patrick Waters; Sarosh Irani; Miriam L Fichtner; Erik S Benotti; Joel M Guthridge; Jennifer Seifert; Richard J Nowak; Jane H Buckner; V Michael Holers; Judith A James; David A Hafler; Kevin C O'Connor
Journal:  J Immunol       Date:  2019-03-01       Impact factor: 5.422

7.  The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.

Authors:  Xiaofei Wang; Ziyan Shi; Zhengyang Zhao; Hongxi Chen; Yanlin Lang; Lingyao Kong; Xue Lin; Qin Du; Jiancheng Wang; Hongyu Zhou
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

Review 8.  Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease.

Authors:  Joseph A Lopez; Martina Denkova; Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Clin Transl Immunology       Date:  2021-07-26

Review 9.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

10.  Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice.

Authors:  Maria M Dimitriadou; Haris Alexopoulos; Sofia Akrivou; Eleni Gola; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.